p66ShcA promotes breast cancer plasticity by inducing an epithelialto-mesenchymal transition

Molecular and Cellular Biology

Volumn 34, Issue 19, 2014, Pages 3689-3701

  Hudson, Jesse ^a   Ha, Jacqueline R ^a   Sabourin, Valerie ^a   Ahn, Ryuhjin ^a   Selva, Rachel La ^a   Livingstone, Julie ^b   Podmore, Lauren ^a   Knight, Jennifer ^b   Forrest, Laura ^a,b   Beauchemin, Nicole ^b,c   Hallett, Michael ^b,c   Park, Morag ^b,c   Ursini Siegel, Josie ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CLAUDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MET PROTEIN TYROSINE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; P66SHCA PROTEIN; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; ERBB2 PROTEIN, HUMAN; MET PROTEIN, HUMAN; PROTEIN SHC; SCATTER FACTOR RECEPTOR; SHC1 PROTEIN, HUMAN; TUMOR MARKER;

ACTIN POLYMERIZATION; ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION; MAMMARY GLAND; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PLASTICITY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; VECTOR CONTROL; WOUND CLOSURE; ANIMAL; BREAST TUMOR; CELL MOTION; EXPERIMENTAL MAMMARY NEOPLASM; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, ERBB-2; SHC SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84906953539     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00341-14     Document Type: Article

References (48)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumours. Nature 406:747-752. http://dx.doi.org/10.1038/35021093.
2. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. 2002. A geneexpression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009. http://dx.doi.org/10.1056/NEJMoa021967.
3. Visvader JE. 2009. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 23:2563-2577. http://dx.doi.org/10.1101/gad.1849509.
4. Gusterson BA, Ross DT, Heath VJ, Stein T. 2005. Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res. 7:143-148. http://dx.doi.org/10.1186/bcr1041.
5. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527. http://dx.doi.org/10.1016/j.ccr.2006.10.008.
6. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12:R68. http://dx.doi.org/10.1186/bcr2635.
7. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA. 2010. Core epithelialto- mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc. Natl. Acad. Sci. U. S. A. 107:15449-15454. http://dx.doi.org/10.1073/pnas.1004900107.
8. Drasin DJ, Robin TP, Ford HL. 2011. Breast cancer epithelial-tomesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res. 13:226. http://dx.doi.org/10.1186/bcr3037.
9. Coˆme C, Magnino F, Bibeau F, De Santa Barbara P, Becker KF, Theillet C, Savagner P. 2006. Snail and slug play distinct roles during breast carcinoma progression. Clin. Cancer Res. 12:5395-5402. http://dx.doi.org/10.1158/1078-0432.CCR-06-0478.
10. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ, Notorfrancesco KL, Cardiff RD, Chodosh LA. 2005. The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8:197-209. http://dx.doi.org/10.1016/j.ccr.2005.07.009.
11. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939. http://dx.doi.org/10.1016/j.cell.2004.06.006.
12. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancone L, Pelicci PG. 1997. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J. 16:706-716. http://dx.doi.org/10.1093/emboj/16.4.706.
13. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Pawson T, Pelicci PG. 1992. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70:93-104. http://dx.doi.org/10.1016/0092-8674(92)90536-L.
14. Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG. 2002. The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J. Biol. Chem. 277:22370-22376. http://dx.doi.org/10.1074/jbc.M200280200.
15. Gu H, Maeda H, Moon JJ, Lord JD, Yoakim M, Nelson BH, Neel BG. 2000. New role for Shc in activation of the phosphatidylinositol 3-kinase/ Akt pathway. Mol. Cell. Biol. 20:7109-7120. http://dx.doi.org/10.1128/MCB.20.19.7109-7120.2000.
16. Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D. 1993. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 363:83-85. http://dx.doi.org/10.1038/363083a0.
17. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG. 1999. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402:309-313. http://dx.doi.org/10.1038/46311.
18. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M, Puri C, Tacchetti C, Ferrini M, Mannucci R, Nicoletti I, Lanfrancone L, Giorgio M, Pelicci PG. 2004. The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. J. Biol. Chem. 279:25689-25695. http://dx.doi.org/10.1074/jbc.M401844200.
19. Gertz M, Fischer F, Wolters D, Steegborn C. 2008. Activation of the lifespan regulator p66Shc through reversible disulfide bond formation. Proc. Natl. Acad. Sci. U. S. A. 105:5705-5709. http://dx.doi.org/10.1073/pnas.0800691105.
20. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, Contursi C, Minucci S, Mantovani F, Wieckowski MR, Del Sal G, Pelicci PG, Rizzuto R. 2007. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 315:659-663. http://dx.doi.org/10.1126/science.1135380.
21. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, Pelicci PG. 2005. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122:221-233. http://dx.doi.org/10.1016/j.cell.2005.05.011.
22. Ahn R, Sabourin V, Ha JR, Cory S, Maric G, Im YK, Hardy WR, Zhao H, Park M, Hallett M, Siegel PM, Pawson T, Ursini-Siegel J. 2013. The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression. Cancer Res. 73:4521-4532. http://dx.doi.org/10.1158/0008-5472.CAN-12-4178.
23. Ursini-Siegel J, Cory S, Zuo D, Hardy WR, Rexhepaj E, Lam S, Schade B, Jirstrom K, Bjur E, Piccirillo CA, Denardo D, Coussens LM, Brennan DJ, Gallagher WM, Park M, Pawson T, Hallett M, Muller WJ. 2010. Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. Cancer Res. 70: 7776-7787. http://dx.doi.org/10.1158/0008-5472.CAN-10-2229.
24. Ursini-Siegel J, Hardy WR, Zheng Y, Ling C, Zuo D, Zhang C, Podmore L, Pawson T, Muller WJ. 2012. The ShcA SH2 domain engages a 14-3- 3/PI3=K signaling complex and promotes breast cancer cell survival. Oncogene 31:5038-5044. http://dx.doi.org/10.1038/onc.2012.4.
25. Ursini-Siegel J, Hardy WR, Zuo D, Lam SH, Sanguin-Gendreau V, Cardiff RD, Pawson T, Muller WJ. 2008. ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J. 27:910-920. http://dx.doi.org/10.1038/emboj.2008.22.
26. Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ, Siegel PM. 2008. Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol. Cell. Biol. 28:3162-3176. http://dx.doi.org/10.1128/MCB.01734-07.
27. Gautier L, Cope L, Bolstad BM, Irizarry RA. 2004. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20:307-315. http://dx.doi.org/10.1093/bioinformatics/btg405.
28. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27:1160-1167. http://dx.doi.org/10.1200/JCO.2008.18.1370.
29. The Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70. http://dx.doi.org/10.1038/nature11412.
30. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM. 2007. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8:R76. http://dx.doi.org/10.1186/gb-2007-8-5-r76.
31. Masi G, Mercati D, Vannuccini E, Paccagnini E, Riparbelli MG, Lupetti P, Pelicci PG, Baldari CT, Ulivieri C. 2014. p66Shc regulates vesiclemediated secretion in mast cells by affecting F-actin dynamics. J. Leukoc. Biol. 95:285-292. http://dx.doi.org/10.1189/jlb.0313178.
32. Patrussi L, Capitani N, Cannizzaro E, Finetti F, Lucherini OM, Pelicci PG, Baldari CT. 2014. Negative regulation of chemokine receptor signaling and B-cell chemotaxis by p66Shc. Cell Death Dis. 5:e1068. http://dx.doi.org/10.1038/cddis.2014.44.
33. Giannoni E, Parri M, Chiarugi P. 2012. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid. Redox Signal. 16:1248-1263. http://dx.doi.org/10.1089/ars.2011.4280.
34. Min C, Eddy SF, Sherr DH, Sonenshein GE. 2008. NF-kappaB and epithelial to mesenchymal transition of cancer. J. Cell. Biochem. 104:733-744. http://dx.doi.org/10.1002/jcb.21695.
35. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL. 2003. Increased malignancy of Neuinduced mammary tumors overexpressing active transforming growth factor beta1. Mol. Cell. Biol. 23:8691-8703. http://dx.doi.org/10.1128/MCB.23.23.8691-8703.2003.
36. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. 2012. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat. Med. 18:74-82. http://dx.doi.org/10.1038/nm.2577.
37. Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M. 2013. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc. Natl. Acad. Sci. U. S. A. 110:E1301-E1310. http://dx.doi.org/10.1073/pnas.1210353110.
38. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull Chughtai SBN, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. 2009. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc. Natl. Acad. Sci. U. S. A. 106:12903- 12908. http://dx.doi.org/10.1073/pnas.0810402106.
39. Ignatiadis M, Sotiriou C. 2013. Luminal breast cancer: from biology to treatment. Nat. Rev. Clin. Oncol. 10:494-506. http://dx.doi.org/10.1038/nrclinonc.2013.124.
40. Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton AR, Jr. 2003. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res. 63: 6772-6783.
41. Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E, Liu Q, Hsieh CC, Bhat G, Frackelton AR, Jr, Hafer LJ. 2007. p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. Clin. Cancer Res. 13:5798-5804. http://dx.doi.org/10.1158/1078-0432.CCR-07-0073.
42. Jackson JG, Yoneda T, Clark GM, Yee D. 2000. Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential. Clin. Cancer Res. 6:1135-1139.
43. Lee MS, Igawa T, Chen SJ, Van Bemmel D, Lin JS, Lin FF, Johansson SL, Christman JK, Lin MF. 2004. p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. Int. J. Cancer 108:672-678. http://dx.doi.org/10.1002/ijc.11621.
44. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno-Sanchez R. 2010. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy. Mol. Aspects Med. 31:145-170. http://dx.doi.org/10.1016/j.mam.2010.02.008.
45. Bubici C, Papa S, Dean K, Franzoso G. 2006. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 25:6731-6748. http://dx.doi.org/10.1038/sj.onc.1209936.
46. Nowsheen S, Aziz K, Kryston TB, Ferguson NF, Georgakilas A. 2012. The interplay between inflammation and oxidative stress in carcinogenesis. Curr. Mol. Med. 12:672-680. http://dx.doi.org/10.2174/156652412800792642.
47. Prasad S, Ravindran J, Aggarwal BB. 2010. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem. 336:25-37. http://dx.doi.org/10.1007/s11010-009-0267-2.
48. Zhang YW, Su Y, Volpert OV, Vande Woude GF. 2003. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl. Acad. Sci. U. S. A. 100:12718-12723. http://dx.doi.org/10.1073/pnas.2135113100.